The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 14, 2014

Filed:

Jun. 04, 2007
Applicants:

Angeline Ingrid Bartholomeusz, Carnegie, AU;

Stephen Locarnini, Balaclava, AU;

Anna Ayre, Brunswick West, AU;

Lilly Ka Wai Yuen, Bulleen, AU;

Peter William Angus, East Ivanhoe, AU;

Joseph John Sasadeusz, Camberell, AU;

Paul Desmond, Albert Park, AU;

Hans Tillman, Leipzig, DE;

Thomas Bock, Tuebingen, DE;

William Sievert, Canterbury, AU;

Sharon Lewin, Armadale, AU;

Inventors:

Angeline Ingrid Bartholomeusz, Carnegie, AU;

Stephen Locarnini, Balaclava, AU;

Anna Ayre, Brunswick West, AU;

Lilly Ka Wai Yuen, Bulleen, AU;

Peter William Angus, East Ivanhoe, AU;

Joseph John Sasadeusz, Camberell, AU;

Paul Desmond, Albert Park, AU;

Hans Tillman, Leipzig, DE;

Thomas Bock, Tuebingen, DE;

William Sievert, Canterbury, AU;

Sharon Lewin, Armadale, AU;

Assignee:

ABL SA, Luxembourg, LU;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/70 (2006.01); A61K 39/00 (2006.01); A61K 39/29 (2006.01); A61K 39/25 (2006.01); C12N 7/00 (2006.01); C07K 14/005 (2006.01);
U.S. Cl.
CPC ...
C12N 7/00 (2013.01); C12N 2730/10134 (2013.01); A61K 39/29 (2013.01); C12N 2730/10122 (2013.01); C07K 14/005 (2013.01);
Abstract

The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.


Find Patent Forward Citations

Loading…